GBI Research’s new report, “Hepatitis Market to 2017 - Strong
Hepatitis-C Pipeline, Large Number of Strategic Consolidations and Cost
Effective Treatments will Drive the Market”, provides in-depth analysis
of the unmet need, drivers and barriers impacting the global hepatitis
market. The report analyzes the hepatitis markets in the US, the top
five countries in Europe (the UK, Germany, France, Italy and Spain) and
Japan. Treatment usage patterns, sales, prices and volumes are forecast
until 2017 for the key geographies as well as the leading therapeutic
segments. The report also provides competitive benchmarking for the
leading companies and analyzes the mergers, acquisitions and licensing
agreements that have shaped the global markets.
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research has found that the global hepatitis market is one of the fast growing markets of the pharmaceutical industry. The approval of potential new drugs and combinational therapies with significant efficacy, safety and resistance profiles will fuel the rapid uptake of drugs in the near future. Limitations of the current standard care therapy for hepatitis include high incidence of adverse events, long duration of treatment, suboptimal patient compliance and the lack of efficacy in specific genotypes. This has increased interest in developing novel products able to potentially counter this unmet need.
Scope
Table of Contents
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Global Hepatitis Market - Introduction 8
2.1 GBI Research Report Guidance 9
3 Global Hepatitis Market - Market Overview 10
3.1 Introduction 10
3.2 Global Hepatitis Therapeutics and Vaccines Market 12
3.3 Revenue Forecasts for the Global Hepatitis Therapeutics Market 13
3.3.1 Revenue 13
3.3.2 Annual Cost of Therapy 14
3.3.3 Treatment Usage Patterns 15
3.4 Hepatitis Market Drivers 21
3.4.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline 21
3.4.2 Promising Developments in Hepatitis C Pipeline 21
3.4.3 Steady Increase in Prescription Population 21
3.5 Hepatitis Market Restraints 21
3.5.1 Hepatitis Rarely Recognized during the Early Stages of the Disease 21
3.5.2 Low Treatment Seeking Population 21
3.5.3 Loss of Exclusivity Protection in Hepatitis B Market 21
3.6 Generic Share in the Global Hepatitis Therapeutics Market 22
4 Global Hepatitis Market - Therapeutic Landscape 23
4.1 Introduction 23
4.1.1 Hepatitis A 23
4.1.2 Hepatitis B 23
4.1.3 Hepatitis C 24
4.2 Overview of Hepatitis A and B Vaccines Market 25
4.2.1 Revenue 25
4.3 Hepatitis B Therapeutics Market 26
4.3.1 Revenue 26
4.3.2 Annual Cost of Therapy 27
4.3.3 Treatment Usage Patterns 28
4.3.4 Geographical Segmentation 33
4.4 Hepatitis C Therapeutics Market 35
4.4.1 Revenue 35
4.4.2 Annual Cost of Therapy 36
4.4.3 Treatment Usage Pattern 37
4.4.4 Geographical Segmentation 43
5 Global Hepatitis Market - Geographical Landscape 45
5.1 Geographical Break-up 45
5.2 The US Hepatitis Therapeutics Market 47
5.2.1 Revenue 47
5.2.2 Annual Cost of Therapy 47
5.2.3 Treatment Usage Patterns 48
5.3 Top Five Countries in Europe Hepatitis Therapeutics Market 55
5.3.1 Revenue 55
5.3.2 Annual Cost of Therapy 57
5.3.3 Treatment Usage Patterns 58
5.4 Japan Hepatitis Therapeutics Market 64
5.4.1 Revenue 64
5.4.2 Annual Cost of Therapy 65
5.4.3 Treatment Usage Patterns 66
6 Global Hepatitis Market - Pipeline Analysis 72
6.1 Introduction 72
6.1.1 Research and Development Pipeline - Hepatitis A Vaccines 74
6.1.2 Research and Development Pipeline - Hepatitis B Therapeutics 75
6.1.3 Research and Development Pipeline - Hepatitis B Vaccines 79
6.1.4 Research and Development Pipeline - Hepatitis C Therapeutics 81
6.2 Molecule Profile for Promising Vaccines for Hepatitis B under Clinical Development 90
6.2.1 Heplisav 90
6.2.2 Spi-VEC 90
6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development 91
6.3.1 Entecavir plus Adefovir Combination Therapy 91
6.3.2 Tenofovir plus Emtricitabine Combination Therapy 91
6.3.3 Pegylated Interferon Alfa-2a + Adefovir 92
6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development 92
6.4.1 Tenofovir + Emtricitabine Combination Therapy 92
6.4.2 Zalbin (albinterferon alfa-2b, Joulferon) 92
6.4.3 RG 7128 94
7 Global Hepatitis Market - Competitive Landscape 95
7.1 Market Share Analysis: Hepatitis 95
7.2 Competitive Profiling 97
7.2.1 Merck & Co., Inc. 97
7.2.2 F. Hoffmann-La Roche Ltd. 99
7.2.3 GlaxoSmithKline plc 100
8 Global Hepatitis Market - Strategic Consolidations 102
8.1 Mergers and Acquisitions 102
8.1.1 Overview 102
8.1.2 Summary of M&A Deals (2010-2011) 104
8.2 R&D Licensing Agreements 105
8.2.1 Summary of Licensing Deals (2010-2011) 105
8.3 Co-Development Deals 108
9 Global Hepatitis Market - Appendix 109
9.1 Market Definitions 109
9.2 Abbreviations 109
9.3 Research Methodology 110
9.3.1 Coverage 110
9.3.2 Secondary Research 110
9.3.3 Primary Research 111
9.4 Therapeutic Landscape 111
9.4.2 Market Size by Geography 113
9.5 Geographical Landscape 114
9.6 Pipeline Analysis 114
9.7 Competitive Landscape 114
9.7.1 Expert Panel Validation 114
9.8 Contact Us 114
9.9 Disclaimer 114
List of Tables
Table 1: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2002-2010 12
Table 2: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2010-2017 12
Table 3: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2010 13
Table 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2010-2017 13
Table 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 14
Table 6: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 14
Table 7: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2002-2010 16
Table 8: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2010-2017 16
Table 9: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2010 25
Table 10: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2010-2017 25
Table 11: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2010 26
Table 12: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2010-2017 26
Table 13: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 27
Table 14: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 27
Table 15: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010 28
Table 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Patterns, 2010-2017 29
Table 17: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010 33
Table 18: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017 34
Table 19: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2010 35
Table 20: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2010-2017 35
Table 21: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 36
Table 22: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 36
Table 23: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010 37
Table 24: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2010-2017 38
Table 25: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2002-2010 43
Table 26: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2010-2017 44
Table 27: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2010 45
Table 28: Hepatitis Market, Global, Revenue by Geography ($m), 2010-2017 46
Table 29: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2010 47
Table 30: Hepatitis Therapeutics Market, The US, Revenue Forecasts ($m),2010-2017 47
Table 31: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2010 48
Table 32: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017 48
Table 33: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern (‘000s), 2002-2010 49
Table 34: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern (‘000s), 2010-2017 50
Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2010 55
Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2010-2017 55
Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 57
Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 57
Table 39: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000s), 2002-2010 58
Table 40: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000s), 2010-2017 59
Table 41: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2010 64
Table 42: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2010-2017 64
Table 43: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 65
Table 44: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 65
Table 45: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000s), 2002-2010 66
Table 46: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000s), 2010-2017 67
Table 47: Hepatitis B Therapeutics Market, Global, Pipeline, 2011 77
Table 48: Hepatitis B Vaccines Market, Global, Pipeline, 2011 80
Table 49: Hepatitis C Therapeutics Market, Global, Pipeline, 2011 83
List of Figures
Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2011 10
Figure 2: Hepatitis Market, Hepatitis Treatment Flow Pathway, 2017 11
Figure 3: Hepatitis Market, Global Therapeutics and Vaccines Market, Revenues ($m), 2002-2017 12
Figure 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2017 13
Figure 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 14
Figure 6: Hepatitis Therapeutics Market, Global, Therapeutic Usage Pattern, 2002-2017 15
Figure 7: Hepatitis Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017 17
Figure 8: Hepatitis Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017 18
Figure 9: Hepatitis Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017 19
Figure 10: Hepatitis Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017 20
Figure 11: Hepatitis Therapeutics Market, Global, Branded and Generic Share (%), 2010-2017 22
Figure 12: Hepatitis Market, Global, Hepatitis B-Genotypes Based on Geographic Origin 24
Figure 13: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2017 25
Figure 14: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2017 26
Figure 15: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 27
Figure 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017 28
Figure 17: Hepatitis B Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017 29
Figure 18: Hepatitis B Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017 30
Figure 19: Hepatitis B Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017 31
Figure 20: Hepatitis B Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017 32
Figure 21: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 33
Figure 22: Hepatitis B Therapeutics Market, Global, Geography Benchmarking, 2010 34
Figure 23: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2017 35
Figure 24: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 36
Figure 25: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017 37
Figure 26: Hepatitis C Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017 39
Figure 27: Hepatitis C Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017 40
Figure 28: Hepatitis C Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017 41
Figure 29: Hepatitis C Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017 42
Figure 30: Hepatitis C Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 43
Figure 31: Hepatitis C Therapeutics Market, Global, Geography Benchmarking, 2010 44
Figure 32: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2017 45
Figure 33: Hepatitis Market, Global, Geography Benchmarking, 2010 and 2017 46
Figure 34: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2017 47
Figure 35: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2017 48
Figure 36: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern, 2002-2017 49
Figure 37: Hepatitis Therapeutics Market, The US, Diseased Population (‘000s), 2002-2017 51
Figure 38: Hepatitis Therapeutics Market, The US, Treatment Seeking Population (‘000s), 2002-2017 52
Figure 39: Hepatitis Therapeutics Market, The US, Diagnosed Population (‘000s), 2002-2017 53
Figure 40: Hepatitis Therapeutics Market, The US, Prescription Population (‘000s), 2002-2017 54
Figure 41: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2017 55
Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 57
Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern, 2002-2017 58
Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population (‘000s), 2002-2017 60
Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population (‘000s), 2002-2017 61
Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population (‘000s), 2002-2017 62
Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population (‘000s), 2002-2017 63
Figure 48: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2017 64
Figure 49: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017 65
Figure 50: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2002-2017 66
Figure 51: Hepatitis Therapeutics Market, Japan, Diseased Population (‘000s), 2002-2017 68
Figure 52: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population (‘000s), 2002-2017 69
Figure 53: Hepatitis Therapeutics Market, Japan, Diagnosed Population (‘000s), 2002-2017 70
Figure 54: Hepatitis Therapeutics Market, Japan, Prescription Population (‘000s), 2002-2017 71
Figure 55: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011 73
Figure 56: Hepatitis Market, Global, R&D Pipeline by Phase (%), 2011 73
Figure 57: Hepatitis B Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 75
Figure 58: Hepatitis B Vaccines Market, Global, R&D Pipeline by Phase (%), 2011 79
Figure 59: Hepatitis C Therapeutics Market Global, R&D Pipeline by Phase (%), 2011 81
Figure 60: Hepatitis B and Hepatitis C Therapeutics Market, Global, Market Share of Top Players (%), 2010 95
Figure 61: Hepatitis Vaccines Market, Global, Market Share of Top Players (%), 2010 96
Figure 62: Hepatitis Market, Merck & Co., Inc., SWOT Analysis, 2011 97
Figure 63: Hepatitis Market, F. Hoffmann-La Roche Ltd., SWOT Analysis, 2011 99
Figure 64: Hepatitis Market, GlaxoSmithKline plc, SWOT Analysis, 2011 100
Figure 65: Hepatitis Therapeutics and Vaccines Market, Global, M&A Deals by Geography (%), 2011 102
Figure 66: Hepatitis Therapeutics and Vaccines Market, M&A Deals by Type (%), 2011 103
Figure 67: Hepatitis Market, Global, Major Licensing Agreements by Indication (%), 2011 105
Figure 68: Hepatitis Market, Global, Major Co-Development Deals by Indication (%), 2011 108
Figure 69: GBI Research Market Forecasting Model 113"
This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.
GBI Research has found that the global hepatitis market is one of the fast growing markets of the pharmaceutical industry. The approval of potential new drugs and combinational therapies with significant efficacy, safety and resistance profiles will fuel the rapid uptake of drugs in the near future. Limitations of the current standard care therapy for hepatitis include high incidence of adverse events, long duration of treatment, suboptimal patient compliance and the lack of efficacy in specific genotypes. This has increased interest in developing novel products able to potentially counter this unmet need.
Scope
- Annualized market data for the hepatitis market from 2002 to 2010, forecast forward to 2017.
- Analysis of the leading segments, including hepatitis A, hepatitis B and hepatitis C.
- Analysis of the hepatitis market in the leading geographies of the world, which include the US, the UK, Germany, France, Italy, Spain and Japan.
- Market characterization of the hepatitis therapeutics market, including market size, annual cost of therapy and treatment usage patterns.
- Key drivers and barriers that have a significant impact on the market.
- Coverage of pipeline molecules in various Phases of drug development.
- Competitive benchmarking of leading companies. The key companies studied in this report are Merck & Co, GlaxoSmithKline and F. Hoffman-La Roche.
- Key M&A activities, licensing agreements that have taken place between 2009 and mid-2011 in the global hepatitis market.
- Align your product portfolio to the markets with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.
- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.
- Develop key strategic initiatives by understanding the key focus areas of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.
Published:January 2012
No. of Pages: 114
No. of Pages: 114
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 6
2 Global Hepatitis Market - Introduction 8
2.1 GBI Research Report Guidance 9
3 Global Hepatitis Market - Market Overview 10
3.1 Introduction 10
3.2 Global Hepatitis Therapeutics and Vaccines Market 12
3.3 Revenue Forecasts for the Global Hepatitis Therapeutics Market 13
3.3.1 Revenue 13
3.3.2 Annual Cost of Therapy 14
3.3.3 Treatment Usage Patterns 15
3.4 Hepatitis Market Drivers 21
3.4.1 Hepatitis C is a Growing Market with Strong Competition and a Promising Pipeline 21
3.4.2 Promising Developments in Hepatitis C Pipeline 21
3.4.3 Steady Increase in Prescription Population 21
3.5 Hepatitis Market Restraints 21
3.5.1 Hepatitis Rarely Recognized during the Early Stages of the Disease 21
3.5.2 Low Treatment Seeking Population 21
3.5.3 Loss of Exclusivity Protection in Hepatitis B Market 21
3.6 Generic Share in the Global Hepatitis Therapeutics Market 22
4 Global Hepatitis Market - Therapeutic Landscape 23
4.1 Introduction 23
4.1.1 Hepatitis A 23
4.1.2 Hepatitis B 23
4.1.3 Hepatitis C 24
4.2 Overview of Hepatitis A and B Vaccines Market 25
4.2.1 Revenue 25
4.3 Hepatitis B Therapeutics Market 26
4.3.1 Revenue 26
4.3.2 Annual Cost of Therapy 27
4.3.3 Treatment Usage Patterns 28
4.3.4 Geographical Segmentation 33
4.4 Hepatitis C Therapeutics Market 35
4.4.1 Revenue 35
4.4.2 Annual Cost of Therapy 36
4.4.3 Treatment Usage Pattern 37
4.4.4 Geographical Segmentation 43
5 Global Hepatitis Market - Geographical Landscape 45
5.1 Geographical Break-up 45
5.2 The US Hepatitis Therapeutics Market 47
5.2.1 Revenue 47
5.2.2 Annual Cost of Therapy 47
5.2.3 Treatment Usage Patterns 48
5.3 Top Five Countries in Europe Hepatitis Therapeutics Market 55
5.3.1 Revenue 55
5.3.2 Annual Cost of Therapy 57
5.3.3 Treatment Usage Patterns 58
5.4 Japan Hepatitis Therapeutics Market 64
5.4.1 Revenue 64
5.4.2 Annual Cost of Therapy 65
5.4.3 Treatment Usage Patterns 66
6 Global Hepatitis Market - Pipeline Analysis 72
6.1 Introduction 72
6.1.1 Research and Development Pipeline - Hepatitis A Vaccines 74
6.1.2 Research and Development Pipeline - Hepatitis B Therapeutics 75
6.1.3 Research and Development Pipeline - Hepatitis B Vaccines 79
6.1.4 Research and Development Pipeline - Hepatitis C Therapeutics 81
6.2 Molecule Profile for Promising Vaccines for Hepatitis B under Clinical Development 90
6.2.1 Heplisav 90
6.2.2 Spi-VEC 90
6.3 Molecule Profile for Promising Therapeutics for Hepatitis B under Clinical Development 91
6.3.1 Entecavir plus Adefovir Combination Therapy 91
6.3.2 Tenofovir plus Emtricitabine Combination Therapy 91
6.3.3 Pegylated Interferon Alfa-2a + Adefovir 92
6.4 Molecule Profile for Promising Therapeutics for Hepatitis C under Clinical Development 92
6.4.1 Tenofovir + Emtricitabine Combination Therapy 92
6.4.2 Zalbin (albinterferon alfa-2b, Joulferon) 92
6.4.3 RG 7128 94
7 Global Hepatitis Market - Competitive Landscape 95
7.1 Market Share Analysis: Hepatitis 95
7.2 Competitive Profiling 97
7.2.1 Merck & Co., Inc. 97
7.2.2 F. Hoffmann-La Roche Ltd. 99
7.2.3 GlaxoSmithKline plc 100
8 Global Hepatitis Market - Strategic Consolidations 102
8.1 Mergers and Acquisitions 102
8.1.1 Overview 102
8.1.2 Summary of M&A Deals (2010-2011) 104
8.2 R&D Licensing Agreements 105
8.2.1 Summary of Licensing Deals (2010-2011) 105
8.3 Co-Development Deals 108
9 Global Hepatitis Market - Appendix 109
9.1 Market Definitions 109
9.2 Abbreviations 109
9.3 Research Methodology 110
9.3.1 Coverage 110
9.3.2 Secondary Research 110
9.3.3 Primary Research 111
9.4 Therapeutic Landscape 111
9.4.2 Market Size by Geography 113
9.5 Geographical Landscape 114
9.6 Pipeline Analysis 114
9.7 Competitive Landscape 114
9.7.1 Expert Panel Validation 114
9.8 Contact Us 114
9.9 Disclaimer 114
List of Tables
Table 1: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2002-2010 12
Table 2: Hepatitis Therapeutics and Vaccines Market, Global, Revenues ($m), 2010-2017 12
Table 3: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2010 13
Table 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2010-2017 13
Table 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 14
Table 6: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 14
Table 7: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2002-2010 16
Table 8: Hepatitis Therapeutics Market, Global, Treatment Usage Pattern (‘000s), 2010-2017 16
Table 9: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2010 25
Table 10: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2010-2017 25
Table 11: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2010 26
Table 12: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2010-2017 26
Table 13: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 27
Table 14: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 27
Table 15: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010 28
Table 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Patterns, 2010-2017 29
Table 17: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2010 33
Table 18: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2010-2017 34
Table 19: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2010 35
Table 20: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2010-2017 35
Table 21: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2010 36
Table 22: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2010-2017 36
Table 23: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2010 37
Table 24: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2010-2017 38
Table 25: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2002-2010 43
Table 26: Hepatitis C Therapeutics Market, Global, Geographical Segmentation, 2010-2017 44
Table 27: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2010 45
Table 28: Hepatitis Market, Global, Revenue by Geography ($m), 2010-2017 46
Table 29: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2010 47
Table 30: Hepatitis Therapeutics Market, The US, Revenue Forecasts ($m),2010-2017 47
Table 31: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2010 48
Table 32: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2010-2017 48
Table 33: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern (‘000s), 2002-2010 49
Table 34: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern (‘000s), 2010-2017 50
Table 35: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2010 55
Table 36: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2010-2017 55
Table 37: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2010 57
Table 38: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2010-2017 57
Table 39: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000s), 2002-2010 58
Table 40: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern (‘000s), 2010-2017 59
Table 41: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2010 64
Table 42: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2010-2017 64
Table 43: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2010 65
Table 44: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2010-2017 65
Table 45: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000s), 2002-2010 66
Table 46: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern (‘000s), 2010-2017 67
Table 47: Hepatitis B Therapeutics Market, Global, Pipeline, 2011 77
Table 48: Hepatitis B Vaccines Market, Global, Pipeline, 2011 80
Table 49: Hepatitis C Therapeutics Market, Global, Pipeline, 2011 83
List of Figures
Figure 1: Hepatitis Market, Global, Drivers and Restraints, 2011 10
Figure 2: Hepatitis Market, Hepatitis Treatment Flow Pathway, 2017 11
Figure 3: Hepatitis Market, Global Therapeutics and Vaccines Market, Revenues ($m), 2002-2017 12
Figure 4: Hepatitis Therapeutics Market, Global, Revenues ($m), 2002-2017 13
Figure 5: Hepatitis Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 14
Figure 6: Hepatitis Therapeutics Market, Global, Therapeutic Usage Pattern, 2002-2017 15
Figure 7: Hepatitis Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017 17
Figure 8: Hepatitis Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017 18
Figure 9: Hepatitis Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017 19
Figure 10: Hepatitis Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017 20
Figure 11: Hepatitis Therapeutics Market, Global, Branded and Generic Share (%), 2010-2017 22
Figure 12: Hepatitis Market, Global, Hepatitis B-Genotypes Based on Geographic Origin 24
Figure 13: Hepatitis Vaccines Market, Hepatitis A and B , Global, Revenues ($m), 2002-2017 25
Figure 14: Hepatitis B Therapeutics Market, Global, Revenues ($m), 2002-2017 26
Figure 15: Hepatitis B Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 27
Figure 16: Hepatitis B Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017 28
Figure 17: Hepatitis B Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017 29
Figure 18: Hepatitis B Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017 30
Figure 19: Hepatitis B Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017 31
Figure 20: Hepatitis B Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017 32
Figure 21: Hepatitis B Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 33
Figure 22: Hepatitis B Therapeutics Market, Global, Geography Benchmarking, 2010 34
Figure 23: Hepatitis C Therapeutics Market, Global, Revenues ($m), 2002-2017 35
Figure 24: Hepatitis C Therapeutics Market, Global, Annual Cost of Therapy ($), 2002-2017 36
Figure 25: Hepatitis C Therapeutics Market, Global, Treatment Usage Pattern, 2002-2017 37
Figure 26: Hepatitis C Therapeutics Market, Global, Diseased Population (‘000s), 2002-2017 39
Figure 27: Hepatitis C Therapeutics Market, Global, Treatment Seeking Population (‘000s), 2002-2017 40
Figure 28: Hepatitis C Therapeutics Market, Global, Diagnosed Population (‘000s), 2002-2017 41
Figure 29: Hepatitis C Therapeutics Market, Global, Prescription Population (‘000s), 2002-2017 42
Figure 30: Hepatitis C Therapeutics Market, Global, Geographical Segmentation ($m), 2002-2017 43
Figure 31: Hepatitis C Therapeutics Market, Global, Geography Benchmarking, 2010 44
Figure 32: Hepatitis Market, Global, Revenue by Geography ($m), 2002-2017 45
Figure 33: Hepatitis Market, Global, Geography Benchmarking, 2010 and 2017 46
Figure 34: Hepatitis Therapeutics Market, The US, Revenue ($m), 2002-2017 47
Figure 35: Hepatitis Therapeutics Market, The US, Annual Cost of Therapy ($), 2002-2017 48
Figure 36: Hepatitis Therapeutics Market, The US, Treatment Usage Pattern, 2002-2017 49
Figure 37: Hepatitis Therapeutics Market, The US, Diseased Population (‘000s), 2002-2017 51
Figure 38: Hepatitis Therapeutics Market, The US, Treatment Seeking Population (‘000s), 2002-2017 52
Figure 39: Hepatitis Therapeutics Market, The US, Diagnosed Population (‘000s), 2002-2017 53
Figure 40: Hepatitis Therapeutics Market, The US, Prescription Population (‘000s), 2002-2017 54
Figure 41: Hepatitis Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2002-2017 55
Figure 42: Hepatitis Therapeutics Market, Top Five Countries in Europe, Annual Cost of Therapy ($), 2002-2017 57
Figure 43: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Usage Pattern, 2002-2017 58
Figure 44: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diseased Population (‘000s), 2002-2017 60
Figure 45: Hepatitis Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population (‘000s), 2002-2017 61
Figure 46: Hepatitis Therapeutics Market, Top Five Countries in Europe, Diagnosed Population (‘000s), 2002-2017 62
Figure 47: Hepatitis Therapeutics Market, Top Five Countries in Europe, Prescription Population (‘000s), 2002-2017 63
Figure 48: Hepatitis Therapeutics Market, Japan, Revenue ($m), 2002-2017 64
Figure 49: Hepatitis Therapeutics Market, Japan, Annual Cost of Therapy ($), 2002-2017 65
Figure 50: Hepatitis Therapeutics Market, Japan, Treatment Usage Pattern, 2002-2017 66
Figure 51: Hepatitis Therapeutics Market, Japan, Diseased Population (‘000s), 2002-2017 68
Figure 52: Hepatitis Therapeutics Market, Japan, Treatment Seeking Population (‘000s), 2002-2017 69
Figure 53: Hepatitis Therapeutics Market, Japan, Diagnosed Population (‘000s), 2002-2017 70
Figure 54: Hepatitis Therapeutics Market, Japan, Prescription Population (‘000s), 2002-2017 71
Figure 55: Hepatitis Market, Global, R&D Pipeline by Indication (%), 2011 73
Figure 56: Hepatitis Market, Global, R&D Pipeline by Phase (%), 2011 73
Figure 57: Hepatitis B Therapeutics Market, Global, R&D Pipeline by Phase (%), 2011 75
Figure 58: Hepatitis B Vaccines Market, Global, R&D Pipeline by Phase (%), 2011 79
Figure 59: Hepatitis C Therapeutics Market Global, R&D Pipeline by Phase (%), 2011 81
Figure 60: Hepatitis B and Hepatitis C Therapeutics Market, Global, Market Share of Top Players (%), 2010 95
Figure 61: Hepatitis Vaccines Market, Global, Market Share of Top Players (%), 2010 96
Figure 62: Hepatitis Market, Merck & Co., Inc., SWOT Analysis, 2011 97
Figure 63: Hepatitis Market, F. Hoffmann-La Roche Ltd., SWOT Analysis, 2011 99
Figure 64: Hepatitis Market, GlaxoSmithKline plc, SWOT Analysis, 2011 100
Figure 65: Hepatitis Therapeutics and Vaccines Market, Global, M&A Deals by Geography (%), 2011 102
Figure 66: Hepatitis Therapeutics and Vaccines Market, M&A Deals by Type (%), 2011 103
Figure 67: Hepatitis Market, Global, Major Licensing Agreements by Indication (%), 2011 105
Figure 68: Hepatitis Market, Global, Major Co-Development Deals by Indication (%), 2011 108
Figure 69: GBI Research Market Forecasting Model 113"
